Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Dyne Therapeutics (DYN) granted inducement equity awards to 17 newly hired employees under Nasdaq Listing Rule 5635(c)(4). The grants comprise stock options to buy up to 213,000 common shares and restricted stock units covering 67,200 common shares.
The options have a ten-year term and an exercise price equal to Dyne’s closing share price on the Nasdaq Global Select Market on November 17, 2026. Both types of awards are scheduled to vest over four years, subject to continued employment through the applicable vesting dates. The grants are governed by the award agreements and Dyne’s 2024 Inducement Stock Incentive Plan.
Positive
- None.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.Options to buy up to 213,000 common shares could dilute shareholders if exercised at the November 17, 2026, closing price.
- Minor point. Forward-looking: it has not happened yet and may not happen.Restricted stock units covering 67,200 common shares could dilute shareholders as shares are issued.
Key Figures
- New hires
- 17 employees
- Employees receiving inducement equity awards
- Stock options
- Up to an aggregate of 213,000 shares
- Options to purchase common stock
- Restricted stock units
- An aggregate of 67,200 shares
- Restricted stock unit awards
- Option term
- 10 years
- Stock options
- Option vesting period
- 4 years
- Subject to continued employee service
- Initial option vesting
- 25%
- On the first anniversary of the applicable employee’s start date
- Subsequent option vesting
- 12 equal quarterly installments
- After the first anniversary, subject to continued service
- Restricted stock unit vesting
- 4 equal annual installments
- Over four years from the applicable employee’s start date
Historical Context
-
Prior grants covered options and RSUs for 16 hires under the same Nasdaq inducement rule.
-
Prior grants used four-year vesting and the same ten-year option term.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
non-statutory stock options financial
restricted stock units financial
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Nov. 19, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to 17 newly hired employees. The awards were made as an inducement material to the newly hired employees’ acceptance of employment with Dyne in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement equity awards consisted of non-statutory stock options to purchase up to an aggregate of 213,000 shares of Dyne’s common stock at a per share exercise price equal to the closing price of Dyne’s common stock on The Nasdaq Global Select Market on November 17, 2026, and restricted stock units with respect to an aggregate of 67,200 shares of Dyne’s common stock. The stock options have a ten-year term and are scheduled to vest over four years, with
The inducement equity awards are subject to the terms and conditions of award agreements covering the grants and Dyne’s 2024 Inducement Stock Incentive Plan.
About Dyne Therapeutics
Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD), Pompe disease and multiple DMD mutations. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.
Contacts:
Investors
Mia Tobias
ir@dyne-tx.com
781-317-0353
Media
Stacy Nartker
media@dyne-tx.com
781-317-1938
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.